Inhibition of PCNA antisense oligonucleotides mediated by liposome on mRNA expression and proliferation of h-RPE cells

Abstract

The proliferating cell nuclear antigen (PCNA) gene expression was blocked and retinal pigment epithelium (RPE) proliferation was inhibited by using antisense oligonucleotides (AS-ODN) mediated by liposome, to find a new genetic therapy of proliferative vitreoretinopathy (PVR). RPE cells cultured in vitro were transfected with synthetic fluoresence labled AS-ODN mediated by liposome-Lipofectamine, and the intracellular distribution and persistence time of AS-ODN were dynamically observed. AS-ODN (0.07, 0.28 and 1.12 μ mol/L and sense oligonucleotides (S-ODN with the same concentrations as AS-ODN) mediated by liposome were delivered to the RPE cells cultured in vitro, and CPM values were measured by ³H-TdR incorporation assay and analyzed statistically by variance by comparison with blank control group. Expression of PCNA mRNA in RPE cells was detected by in situ hybridization after the treatment of different concentrations of PCNA AS-ODN and S-ODN, and the average optic density (AOD) was measured by image analysis system and was subjected to q-test and correlation analysis with CPM. Our results showed that AS-ODN mediated by liposome could quickly aggregate in cellular plasma and nuclei in 30 min and 6 h, and stayed for as long as 6 days. AS-ODN (0.28 and 1.12 μ mol/L) markedly suppressed proliferation of RPE cells in a dose-dependent manner with the difference being statistically significant (P<0.05 and P<0.01, repectively) as compared with blank control group. AOD was well correlated with CPM (r=0.975). It is concluded that liposome could increase transfection efficiency of AS-ODN in RPE cells, and AS-ODN could sequence-specifically suppress PCNA mRNA expression and proliferation of human RPE cells.

Keywords

human retinal pigment epithelium cell / antisense oligonucleotides / proliferating cell nuclear antigen

References

[1] FloodM. T., GourasP., KjeldbyeH.. Growth characteristics and ultra-structure of human retinal pigment epithelium in vitro. Invest Ophthalmol Vis Sci, 1980, 19: 1309-1320

[2] MannM. J., GibbonsG. H., KernoffR. S., et al.. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA, 1995, 92(10): 4502-4506

[3] MckechnieN. M., BoultonM., RobeyH. L., et al.. The cytoskeletal element of human retinal pigment epitherlium: in vitro and in vivo. J Cell Sci, 1988, 91: 303-312

[4] FelgnerP. L., GadekT. R., HolmM., et al.. Lipofectin: a hightly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA, 1987, 84: 7413-7417

[5] TariA., KhodadadianM., EllersonD., et al.. Liposomal delivery of oligodeoxynucleotides. Leuk Lymphoma, 1996, 21: 93-97

[6] JerdanJ. A., PeposeJ. S., MiechelR.G., et al.. Proliferative vitreoretinopathy membrances. An immunohistochemical study. Ophtholmol, 1989, 96: 801-810

[7] LiuY. C., MarraccinoR. L., KengP. C., et al.. Requirement for proliferating cell nuclear antigen expression during stages of the Chinese hamster ovary cell cycle. Biochemistry, 1989, 28(7): 2967-2974

[8] JaskulskiD., deRielJ. K., MercerW. E., et al.. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science, 1988, 240(4858): 1544-1546

[9] ColmanA.. Antisense strategies in cell and developmental biology. J Cell Sci, 1990, 97: 399-409

[10] SteinC., CohenJ.. Oligodeoxynucleotides as inhibitors of gene express: A review. Cancer Res, 1988, 48: 2659-2688

[11] HaustD. A., MoreR. H., MovatH. Z.. The role of smooth muscle cell in fibrogenesis of arterosclerosis. Am J Pathol, 1960, 37: 377-388

[12] MorishitaR., GibbonsG. H., EllisonK. E., et al.. Single intraluminal delivery of antisense cdc2kinase and proliferating-cell nuclear antigen oligonucleotides results in chroric inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA, 1993, 90(10): 8474-8478

[13] MannM. J., GibbonsG. H., TsaoP. S., et al.. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest, 1997, 99(6): 1295-1301